Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.